F-star

To Progress Product Candidates Into Development and Maximise Potential of the Modular Antibody Technology Platform

Older News

VIENNA, Austria, April 13, 2011 - f-star GmbH, a biopharmaceutical company developing a new generation of antibody based products using its Modular Antibody Technology platform, today announced the closing of a EUR 15 Million financing.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy